Key result
Statins are associated with an increased risk of new-onset diabetes that varies by statin type and dose, highlighting the need for individualized therapy based on patient cardiovascular and metabolic risk profiles.
Why the study?
Does statin therapy increase the risk of new-onset diabetes mellitus in patients at risk of cardiovascular events?
Population
Patients receiving statin therapy for primary or secondary cardiovascular prevention
Comparison
Statin therapy at moderate or intensive doses vs Placebo or lower-dose statin therapy
Design
Review
Authors
Loading...
May guide statin choice by type and dose in patients with metabolic risk; leaves open the need for randomized confirmation of absolute increments.
Does statin therapy increase the risk of new-onset diabetes mellitus in patients at risk of cardiovascular events?
While statins carry a small, molecule- and dose-dependent risk of inducing new-onset diabetes, their cardiovascular benefits significantly outweigh this risk, emphasizing the need for individualized statin selection.
Navarese et al. (2013) conducted a review in Hyperlipidemia and Cardiovascular Disease. Statins vs. Placebo or lower dose statins was evaluated. Statins are associated with an increased risk of new-onset diabetes that varies by statin type and dose, highlighting the need for individualized therapy based on patient cardiovascular and metabolic risk profiles.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: